Microbio Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023
Share
Microbio Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 358.7 million compared to TWD 475.26 million a year ago. Revenue was TWD 366.94 million compared to TWD 483.28 million a year ago. Net loss was TWD 492.58 million compared to TWD 560.95 million a year ago. Basic loss per share from continuing operations was TWD 0.88 compared to TWD 1 a year ago. Diluted loss per share from continuing operations was TWD 0.88 compared to TWD 1 a year ago.
For the six months, sales was TWD 739.35 million compared to TWD 869.4 million a year ago. Revenue was TWD 754.53 million compared to TWD 885.3 million a year ago. Net loss was TWD 598.55 million compared to net income of TWD 246.29 million a year ago. Basic loss per share from continuing operations was TWD 1.07 compared to basic earnings per share from continuing operations of TWD 0.44 a year ago. Diluted loss per share from continuing operations was TWD 1.07 compared to diluted earnings per share from continuing operations of TWD 0.44 a year ago.
Microbio Co., Ltd. is a Taiwan-based company primarily engaged in the research, development, manufacture, distribution and wholesales of healthcare food products and pharmaceuticals. The Company provides fermentation products, including Tien Chun Bao (TCB) oral solutions; herbal products, including LeeHerb series products, as well as organic foods, including vegetables, fruits, nuts, pastry, seasonings, organic meals and others. In addition, it provides new medicines, including anticancer medicines, medicines for hepatitis, allergy, rheumatoid arthritis and others. The Company mainly distributes its products mainly within domestic market.
MICROBIO CO., LTD. 
